Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
34%
Contact Information
Credentials/Degree (MD, DO, etc.)
Date of  Participation
Each of the following represents LAG-3 inhibitors that are used in dual immune checkpoint blockade to treat metastatic melanoma, EXCEPT: 
In the RELATIVITY-047 trial, what percentage of patients discontinued the fixed-dose combination of nivolumab and relatlimab due to adverse events?
A 58-year-old man presents with fatigue and hard black nodules on his arm. He has controlled hypertension. He is diagnosed with metastatic melanoma, with an ECOG of 1. Various scans show that the cancer has metastasized to the lung, bone, and lymph nodes. He is BRAF V600K mutation negative and he has elevated liver transaminases. His renal function is normal, but serum LDH is 8500 U/L. Which is the following would be the most appropriate first-line therapy for this patient? 
What is your job role?
What is your type of practice?
How many years have you been in practice?
Please estimate the number of patients with melanoma that you provide for weekly:
Powered by QuestionPro